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The beneficial role of left ventricular assist
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Left ventricular assist devices (LVADs) are increasinglyused as destination therapy for patients with end-stageheart failure who are unsuitable for cardiac transplan-tation.1-3 There are few data regarding patients placed
on LVADs intended for destination therapy whose improvement
eventually allows for listing for cardiac transplantation. We report
our experience with such a group of patients.
Clinical Summary
Between January 2000 and September 2004, 15 patients received
destination LVAD therapy in our institution. Nine patients had
received the Novacor device as part of the INTrEPID (Investiga-
tion of Non-Transplant-Eligible Patients who are Inotrope Depen-
dent) trial, and 6 had received the HeartMate XVE device (Thor-
atec Corporation) after US Food and Drug Administration
approval was granted for destination therapy. From this group, 6
patients were reevaluated and listed for transplantation. The mean
age was 52 years (range, 31-66 years). The cause of the underlying
cardiomyopathy was ischemic in 4 patients, idiopathic in 1 patient,
and adriamycin-induced heart failure in 1 patient. Contraindica-
tions for cardiac transplantation before LVAD destination therapy
were irreversible severe pulmonary hypertension in 5 patients, 2 of
whom also had concomitant renal insufficiency and 1 of whom had
a recent history of treated endometrial cancer (Table 1). After
LVAD implantations, significant reduction in pulmonary arterial
pressure, pulmonary vascular resistance, and renal function was
seen in these patients (Table 2). Heart transplantation was initially
contraindicated in another patient because of psychosocial history
and poor compliance. The mean duration of LVAD support until
listing among the 6 patients was 243 days (range, 88-684 days).
Four patients have undergone transplantation and are alive at a
mean duration of 33 months (range, 8-55 months; Table 1). One
patient is still on the waiting list, and 1 died from a hemorrhagic
cerebrovascular acci-
dent before undergoing
transplantation. In the
one patient with can-
cer, there has been no evidence of recurrence. None of the patients
who underwent transplantation with previous pulmonary hyperten-
sion had significant perioperative right ventricular dysfunction.
The remaining 9 patients with LVAD destination therapy were
not offered heart transplantation because of either the presence of
ongoing contraindications to heart transplantation or perioperative
death after LVAD implantation. The contraindications to heart
transplantation in these 9 patients were significant comorbidity in
3 patients, advanced age in combination with significant comor-
bidity in 3 patients, and malignancy in 2 patients. At a mean
follow-up of 200 days (range, 1-1095 days), 5 patients were
deceased, whereas the remaining patients were still alive. The
causes of death in the 5 patients were multiorgan failure in 3
patients, traumatic hemorrhagic cerebrovascular accident after a
motor vehicle accident in 1 patient, and intraoperative death in 1
patient.
Discussion
Cardiac transplantation has been the conventional surgical treat-
ment for patients with late-stage heart failure who are not amena-
ble to other cardiac surgical therapy, such as coronary artery
bypass or valvular surgery.4 For patients with pulmonary hyper-
tension, eligibility for listing for cardiac transplantation depends
on the demonstration of reversibility of the high pulmonary vas-
cular resistance with vasodilators, such as nitroprusside, nitroglyc-
erin, prostacyclin, or inhaled nitric oxide. In general, it is prefer-
able to demonstrate a reduction of pulmonary vascular resistance
to 4 Wood units or less before patients are considered suitable for
transplantation. In the setting of end-stage heart failure, sometimes
it can be difficult to establish the reversibility of pulmonary hy-
pertension. Pharmacologic options to unload the left heart are
limited, and uptitration of vasodilator drugs is associated with
systemic hypotension. Patients found to have severe irreversible
pulmonary hypertension are therefore precluded from consider-
ation for cardiac transplantation or LVAD therapy as a bridge to
transplantation.
The REMATCH trial was a landmark prospective trial in
patients ineligible for heart transplantation that demonstrated the
survival advantage of patients treated with an LVAD compared
with those receiving optimal medical therapy.1 The results of this
study provided the major impetus for the US Food and Drug
Administration to grant approval in November 2002 for the use of
the HeartMate device as destination therapy for patients ineligible
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for cardiac transplantation.2,3 Despite a rapid proliferation of cen-
ters recognized by the Centers for Medicare and Medicaid Services
as meeting the criteria for LVAD implantation, to date, only 175
HeartMate destination therapy implantations have been done since
the REMATCH trial (personal communication on November 29,
2004, from Jerry Heatley, Manager, Clinical Data Systems, and
Biostatistician, Thoratec Corporation, 23 Fourth Ave, Burlington,
MA 01803; E-mail: jerry.heatley@thoratec.com). This low num-
ber of implantations is likely a reflection of the relatively high
number of complications reported by the REMATCH investiga-
tors, most notably issues regarding device durability.1 Continued
improvement in this and other ventricular assist device technolo-
gies will likely continue to decrease complications associated with
device implantation and incidence of mechanical failure. However,
until further improvements are implemented and demonstrated,
cardiac transplantation remains the gold standard for the treatment
of end-stage heart failure.4
Use of LVADs as destination therapy now offers an added
dimension to caring for patients with severe end-stage heart failure
who have relative contraindications to transplantation that might
potentially be remedied. In our patients the gradual improvement
of significant pulmonary hypertension was seen in 5 patients after
destination therapy. These improvements eventually allowed list-
ing for cardiac transplantation, and 4 patients underwent successful
transplantation. Improvement in pulmonary vascular resistance
with LVAD support has been observed previously, and one pos-
sible explanation is that maximal unloading of the heart removes
secondary pulmonary hypertension as a contributing factor. It is
also possible that the unloading of the heart might have allowed for
actual reverse remodeling of the pulmonary arteries, such as de-
creased medial hypertrophy over time.
The intent of this report is to emphasize the importance of
continued reevaluation of LVAD destination therapy patients for
significant improvement and reversal of relative contraindications
that would allow for consideration for transplantation, especially
as predictable device end-of-life approaches or complications,
such as localized device infection, occur. This therapy might be
particularly beneficial to patients with curable forms of cancer or
those with pharmacologically irreversible pulmonary hyperten-
sion.
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TABLE 1. Initial contraindications to cardiac transplantation and outcomes after intended LVAD destination therapy
Patient no. Contraindications to cardiac transplantation Outcomes after intended LVAD destination therapy
1 Pulmonary hypertension and renal insufficiency Resolution of pulmonary hypertension and renal insufficiency,
followed by successful cardiac transplantation
2 Pulmonary hypertension and renal insufficiency Resolution of pulmonary hypertension and renal insufficiency;
death caused by cerebrovascular accident
3 Pulmonary hypertension and treated
endometrial carcinoma
Resolution of pulmonary hypertension and no recurrence of
carcinoma, followed by successful cardiac transplantation
4 Pulmonary hypertension Resolution of pulmonary hypertension, followed by successful
cardiac transplantation
5 Pulmonary hypertension Resolution of pulmonary hypertension; listed for cardiac
transplantation
6 Psychosocial history: smoker, poor compliance,
and poor social support
Improvement in compliance, developed good social support,
and ceased smoking; successful cardiac transplantation
LVAD, Left ventricular assist device.
TABLE 2. Hemodynamic parameters and serum creatinine
level before and after LVAD implantation
Mean (range)
PAP, mm Hg
(n  5)
Mean (range)
PVR, Wood
units (n  5)
Mean (range)
creatinine, mg/dL
(n  2)
Before LVAD 46 (41-50) 5.5 (2.5-12) 2.8 (2.7-2.9)
After LVAD 23 (12-30) 2.1 (0.9-3) 1.15 (0.8-1.5)
LVAD, Left ventricular assist device; PAP, pulmonary arterial pressure;
PVR, pulmonary vascular resistance.
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